Ftse Mib
33.308,77
-1,09%
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
NASDAQ
17.689,36
-0,18%
Bitcoin
64.072,95
-0,27%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Anebulo Pharmaceuticals Inc (ANEB) Anebulo Pharmaceuticals Inc (ANEB) Notizie

ANEB

Anebulo Pharmaceuticals (ANEB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANEB
DataOraFonteTitoloSimboloCompagnia
17/06/202422:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
17/06/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202422:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202419:05Business WireAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
13/02/202422:05Business WireAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202322:05Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202314:31Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202314:22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
19/10/202323:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202322:06Business WireAnebulo Pharmaceuticals Announces New CEONASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202322:06Business WireAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/10/202323:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
22/09/202322:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
20/09/202322:29Business WireAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/08/202314:00Business WireAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
21/08/202314:00Business WireAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionNASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202322:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202314:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202314:00PR Newswire (US)Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/04/202300:33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
28/03/202314:00PR Newswire (US)Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/03/202314:00PR Newswire (US)Anebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/02/202314:38Business Wire Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/01/202314:00Business WireAnebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202212:13Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/11/202214:00Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/11/202221:07Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
01/11/202221:00Business WireAnebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
17/10/202215:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/10/202212:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANEB

La tua Cronologia

BIT
NSCIT2236023
IBRD
BIT
SRIC5
BNP Paribas Easy EUR Cor...
BIT
FLEQ
Franklin Temp ICAV - Fra...
LSE
CAV
Cavendish Financial
LSE
RI26
Newday Fmi 30 S
USOTC
EQMEF
Equity Metals (QB)
LSE
90LM
Nthnbn.1.6274%
BOV
TKNO4F
TEKNO PN
TG
A2RRZZ
A T and T
TG
DHY486
Deutsche Hypothekenbank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network